Camlin Fine Sciences Ltd. Rights Issue (Camlin Fine Sciences Rights Issue 2024) Detail

₹224.69 Crores | Listing at BSE, NSE | Fri, Jan 17, 2025 - Mon, Jan 27, 2025

Camlin Fine Sciences Ltd. Logo

Camlin Fine Sciences Ltd. Rights Issue comprises 2.04 Cr equity shares aggregating to ₹224.69 Cr, offered at an issue price of ₹110 per share with a face value of ₹1 per share.

The record date for determining eligible shareholder is Jan 8, 2025, with the Rights Issue being offered in the entitlement ratio of 5 : 41.

The term of payment is defined as following : The full amount of Issue Price of Rs. 110/-per Rights Equity Share is payable on Application.

The Rights Entitlements are expected to be credited to eligible demat accounts on Jan 31, 2025.

The Rights Issue opens on Jan 17, 2025, and closes on Jan 27, 2025, with renunciation of Rights Entitlements permitted up to Jan 21, 2025.

The deemed date of allotment is Jan 31, 2025, following which the equity shares are expected to be credited to demat accounts on Feb 5, 2025 and listed at the NSE and the BSE on Feb 7, 2025.

Centrum Capital Ltd. is the Lead Manager to the issue and MUFG Intime India Pvt.Ltd. is the Registrar to the Issue.

Investors are advised to refer to the Camlin Fine Sciences Ltd. Letter of Offer for detailed information, including risk factors, issue terms, and procedural details.

Record Date

Wed, Jan 8, 2025

Entitlement Ratio

5 : 41

Open Date

Fri, Jan 17, 2025

Close Date

Mon, Jan 27, 2025

Rights Issue Details

Rights Issue Timetable

Camlin Fine Sciences Ltd. Financial Information (Restated Consolidated)

Period Ended31 Mar 202431 Mar 202331 Mar 2022
Assets1,951.722,060.11,800.08
Revenue1,628.621,687.361,445.12
Profit After Tax-104.8839.8160.37
Amount in ₹ Crore

About Camlin Fine Sciences Ltd.

Camlin Fine Sciences Ltd (CFS) is an Indian company that manufactures and sells chemicals, ingredients, and additive blends for various industries

CFS produces antioxidants like tert-butylhydroquinone (TBHQ) and Butylated hydroxyanisole (BHA).They also offer shelf-life extension solutions like bactericides, mould inhibitors, and disinfectants.

CFS provides performance chemicals like hydroquinone and catechol to the pharmaceutical industry. The company also manufactures aroma ingredients for food, beverages, flavor, fragrances, and incense sticks.

CFS has manufacturing facilities in India and Italy and offices and R&D centres in Europe, North and South America, and Asia.They sell their products through a supply chain network in North, Central, and South America, Europe, and Asia-Pacific.

Objects of the Issue:

The Company intends to utilize the Net Proceeds from the Issue towards funding the following objects:

  1. Prepayment and/or repayment, in full or in part, of certain borrowings availed by the Company; and
  2. General corporate purposes.

Rights Issue Review

[Dilip Davda] The company is a global player for manufacturing/marketing speciality chemicals and blends used by varied industries. It posted losses from FY24 onwards, that raises major concern. Based on recent trends, the issue appears aggressively priced. Widening losses for the pre-RI period not only raise eyebrows, but also concern over its fate in near term. The counter is well managed above the RI price to tempt investors. Well-informed investors may park moderate funds for long term. Read detail review...

Rights Issue Subscription Status

Camlin Fine Sciences Rights Issue 2024 got oversubscribed by 1.66 times by the end of the bidding period with total bid quantity received by BSE and NSE of 3,39,15,664 shares. Check Day by Day Subscription Details (Live Status)

DateBSE Bid QuantityNSE Bid Quantity Total Bid Quantity Subscription Times

Jan 27 2025 16:30:00

3,10,87,353

28,28,311

3,38,64,903

1.66x

Company Contact Information

Camlin Fine Sciences Ltd.
Floor 2to 5, Building in GS. Point, Plot No. VIII
Private Layout Scheme, Opp. University Campus,
C.S.T. Road, Kalina, Santa-Mumbai-400098
Mumbai, Maharashtra, 400098

Rights Issue Registrar

MUFG Intime India Pvt.Ltd.

Rights Issue Lead Manager(s)

  1. Centrum Capital Ltd.

Rights Issue FAQs

The Camlin Fine Sciences Rights Issue 2024 opens on Fri, Jan 17, 2025, and closes on Mon, Jan 27, 2025.

Camlin Fine Sciences Rights Issue 2024 Schedule

Last Date for credit of Rights EntitlementsMon, Jan 13, 2025
Last Date for renunciation of Rights EntitlementsTue, Jan 21, 2025
Issue Opening DateFri, Jan 17, 2025
Issue Closing DateMon, Jan 27, 2025
Date of Allotment (on or about)Fri, Jan 31, 2025
Date of Credit (on or about)Wed, Feb 5, 2025
Date of Listing (on or about)Fri, Feb 7, 2025
Camlin Fine Sciences Rights Issue 2024 price is set at ₹110 per share.
The eligible shareholders are being offered 5 Rights Equity Share(s) for every 41 fully paid-up Equity Shares held on Record Date (Wed, Jan 8, 2025).
The record date for the Camlin Fine Sciences Rights Issue 2024 is Wed, Jan 8, 2025.
The issue size of Camlin Fine Sciences Rights Issue 2024 is of 2,04,26,244 equity shares at ₹110 per share aggregating up to ₹224.69 Crores.
The Letter of Offer for Camlin Fine Sciences Rights Issue 2024 can be downloaded here.

You can apply for Camlin Fine Sciences Rights Issue 2024 in two ways:

  1. Net Banking (ASBA)
  2. Registrar's Website (R-WAP Facility)

Steps to apply for Camlin Fine Sciences Rights Issue 2024 using Net Banking (ASBA)

  1. Log in to the net banking account of your bank.
  2. Go to the 'IPO & Rights Issue' section.
  3. Check if the Camlin Fine Sciences Rights Issue 2024 is available on the list.
  4. Click the Apply button next to the Camlin Fine Sciences Rights Issue 2024.
  5. Fill and check your information.
  6. Submit the application.

Steps to apply for Camlin Fine Sciences Rights Issue 2024 using Registrar's website (R-WAP)

  1. Visit registrar's website
  2. Go to the 'Rights Issue' section
  3. Select Camlin Fine Sciences Rights Issue 2024 from the dropdown.
  4. Enter Demat Account Number.
  5. Fill the online application form.
  6. Validate and submit the application.

Compare: